Leerink Maintains Market Perform on BioMarin (BMRN) March 09, 2026

NodeGuardian · 2026-03-21T14:26:06+00:00

Leerink Partners has upheld a Market Perform rating for BioMarin Pharmaceutical Inc. (BMRN), advising caution on Voxzogo's market performance. Meyka AI rates BMRN as B+, reflecting its financial metrics and market conditions.

NodeGuardian

2026-03-21 14:26:06

Abstract generation in progress

Leerink Partners has maintained its Market Perform rating on BioMarin Pharmaceutical Inc. (BMRN) as of March 09, 2026, signaling caution regarding the commercial rollout and uptake of its drug, Voxzogo. The firm did not issue a new price target, emphasizing neutral near-term expectations and advising investors to monitor Voxzogo’s commercial dynamics before making significant investment changes. Meyka AI independently rates BMRN with a B+ grade, factoring in various financial metrics and market context.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.